6Giuseppe M, Guy DB, Anna D,et al. 2007 Guidelines for management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [ J ]. J Hypertension, 2007, 25 (6) : 1105 - 1187.
7Miura S. Do all angiotensin Ⅱ type 1 receptor blockers have the same beneficial effects [ J ] ? Br J Pharmacol, 2007,151 (7) : 912 - 913.
8Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin Ⅱ type 1 receptor[J]. J Biol Chem, 2006, 281(28): 19288- 19295.
9Yoshida K, Kohzuki M. Clinical and experimental aspects of olmsartan medoxomil, a new angiotensin Ⅱ receptor antagonist [ J ]. Cardiovasc Drug Rev, 2004, 22 (4) : 285 - 308.
10Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmsartan medoxomil,losrtan potassium, valsartan, and irbesartan [J]. Am J Cardiovasc Drugs, 2005, 5(1): 41 -50.
